NCT07276867 Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity
| NCT ID | NCT07276867 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Intrathecal |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2025-10-20 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 58 participants in total. It began in 2025-10-20 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.
Eligibility Criteria
Inclusion Criteria: * Age from 18 to 60 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status of II-III. * Height between 150-185 cm. * Body mass index between 18-35 kg/m². * Scheduled for above-knee amputation due to lower limb sarcomas. Exclusion Criteria: * Allergy to any of the investigated drugs. * History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors. * Contraindications to spinal anesthesia. * Pregnancy or lactation. * Presence of psychiatric illness or chronic pain conditions.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07276867 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Intrathecal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07276867 currently recruiting?
Yes, NCT07276867 is actively recruiting participants. Contact the research team at mai.elrawas@nci.cu.edu.eg for enrollment information.
Where is the NCT07276867 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07276867 clinical trial?
NCT07276867 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 58 participants.